Literature DB >> 2494618

The association of antiphospholipid antibodies with severe preeclampsia.

D W Branch1, R Andres, K B Digre, N S Rote, J R Scott.   

Abstract

Over a 3-year period, we studied 43 women who presented with severe preeclampsia prior to 34 weeks' gestation. Seven (16%) had significant levels of antiphospholipid antibodies, whereas none of the normotensive controls of similar gestational age had antiphospholipid antibodies (P less than .001). Three of the seven women with antiphospholipid antibodies suffered the following complications during the peripartum period: 1) cerebral infarction and episodes of transient monocular blindness; 2) pulmonary embolism, deep venous thrombosis, and an autoimmune flare in the postpartum period; and 3) transient monocular blindness and amnesia after delivery. Our experience suggests that antiphospholipid antibodies are found in a substantial proportion of cases of early-onset severe preeclampsia and have important clinical implications. We suggest that patients with early-onset severe preeclampsia be screened for antiphospholipid antibodies; if antibodies are detected, these women should be considered for prophylactic anticoagulation therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2494618

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  19 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Antiphospholipid syndrome: laboratory testing and diagnostic strategies.

Authors:  Thomas L Ortel
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

3.  Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.

Authors:  Karoline Mayer-Pickel; Katharina Eberhard; Uwe Lang; Mila Cervar-Zivkovic
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 4.  Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies.

Authors:  Kirsten Duckitt; Deborah Harrington
Journal:  BMJ       Date:  2005-03-02

Review 5.  Lupus and pregnancy: complex yet manageable.

Authors:  Josephine Patricia Dhar; Robert J Sokol
Journal:  Clin Med Res       Date:  2006-12

Review 6.  Evaluation of the obstetrical risks of the antiphospholipid syndrome and therapeutic management.

Authors:  P Edelman; A M Rouquette
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

7.  The Fetal Safety of Enoxaparin Use During Pregnancy: A Population-Based Retrospective Cohort Study.

Authors:  Meital Shlomo; Rafael Gorodischer; Sharon Daniel; Arnon Wiznitzer; Ilan Matok; Boris Fishman; Gideon Koren; Amalia Levy
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

8.  Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study.

Authors:  K J Gibbins; A E Tebo; S K Nielsen; D W Branch
Journal:  Lupus       Date:  2018-07-20       Impact factor: 2.911

9.  Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for factor V Leiden.

Authors:  Tracy Manuck; D Ware Branch; Yinglei Lai; Baha Sibai; Catherine Y Spong; George Wendel; Katharine Wenstrom; Philip Samuels; Steve N Caritis; Yoram Sorokin; Menachem Miodovnik; Mary J O'Sullivan; Deborah Conway; Ronald J Wapner
Journal:  J Reprod Immunol       Date:  2010-05-02       Impact factor: 4.054

10.  Measurement of antiphospholipid antibody by ELISA using purified beta 2-glycoprotein I in preeclampsia.

Authors:  T Yamamoto; S Yoshimura; Y Geshi; Y Sasamori; S Okinaga; T Kobayashi; H Mori
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.